Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome
Recruiting
Phase 4
Interventional Study
Metabolic Syndrome
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 35 – 65
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 220 (estimated)
- Sponsor
- University Medical Center, Kazakhstan · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Background. The prevalence of type 2 diabetes mellitus (T2D) in the world is constantly increasing. Treatment of T2D is complicated by arterial hypertension and obesity (metabolic syndrome - MS). Cardiovascular complications are the main cause of death in patients with MS. Objective weight loss improves clinical and laboratory parameters in patients with T2D and hypertension.
Purpose: To study li…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* written informed consent;
* T2D≥3-year with glucose lowering therapy including insulin;
* 35-55 years old;
* BMI≥27 kg/m2 for both sex, for Asian ethnicity;
* ongoing treatment with antihypertensive treatment;
* weight loss 15-20% at baseline and dynamic follow-up up to 24 wee…
Contacts